Improving AD patients' cognitive indicators Innovative oral therapy reaches phase 2b/3 clinical major...

AB Science announced today that it has reached its intended primary endpoint in a Phase 2b/3 clinical trial of the oral therapy masitinib in the treatment of patients with mild and moderate Alzheimer's disease.
significantly improved changes in memory and cognitive indicators compared to placebos.
Alzheimer's disease is a progressive neurological disorder that impairs thinking, memory and independence and leads to premature death.
the disease is a growing global health crisis affecting patients and their families.
tens of millions of people worldwide suffer from Alzheimer's disease, and that number will continue to grow in the coming years, according to the World Health Organization.
, developed by AB Science, is a tyrosine kinase inhibitor.
it has a dual mechanism of action, on the one hand, by specifically inhibiting the activity of c-Kit, Lyn, and Fyn protein kinases, it can inhibit the activation of fat cells (mast cells).
cells are important targets in neurodegenerative diseases, inflammatory diseases and oncology.
their activation-mediated inflammatory response may be one of the factors that occur with Alzheimer's disease.
addition, masaitini is also able to target macrophages/small glial cells by inhibiting MCSFR-1 activity.
these cells also play an important role in the inflammatory response to Alzheimer's disease.
(Photo: AB Science) In a randomized, placebo-controlled international phase 2b/3 clinical study, mild and moderate patients were treated with a cholinesterase inhibitor and/or memantine, respectively, while receiving cholinesterase inhibitors and/or memantine.
test results showed that the ADAS-Cog score (a tool for measuring the effects on cognition and memory) of patients in the maseratini group (n-182) improved significantly compared to the baseline (p-0.0003) to reach the main end of the trial.
ADCS-ADL scores, which assess patients' self-care and daily activities at the same time, also showed significant changes.
compared to the placebo group, the number of patients in the Maseratini group who developed severe dementia (MMSE-lt;10) decreased significantly after 24 weeks of treatment.
This positive result in the treatment of Alzheimer's disease further validates the mechanism by which mastasinib is used in neurodegenerative diseases," said Professor Olivier Hermine, chairman of the AB Science Scientific Committee and a member of the French Academy of Sciences.
previously, Masaitini has had positive results in phase 2b/3 clinical trials for the treatment of amyotrophy lateral sclerosis (ALS) and advanced multiple sclerosis.
The three studies clearly show that targeting congenital immune systems, including macrophages/small glial cells and hypertrophic cells, is an effective strategy for treating neurodegenerative diseases by inhibiting tyrosine kinases like mastatin.
" AB Science plans to present detailed findings at an upcoming medical conference.
: . Retrieved December 16, 2020, from AB Science Corporate Presentation. Retrieved December 16, 2020, from